当社は世界中に25以上- We will enhance the quality and stable supply of pharmaceuticals with AI and digital technology.
- We will expand the successful cases at each manufacturing base globally.
We would like to inform you that we have announced our efforts in manufacturing digital transformation (DX) as part of our global program, 'Factory of the Future.'
'Factory of the Future' is a program in which all of our manufacturing bases undergo transformation in three aspects: strengthening digital education and change management, digitalization and automation, and pursuing productivity and efficiency, according to the roadmap created based on the functions and pharmaceuticals manufactured at each base.
In our manufacturing DX efforts, we will utilize advanced technologies such as AI, digital twin, and big data analysis to accelerate innovation at our manufacturing bases worldwide. By doing so, we will enhance the quality and stable supply of pharmaceuticals and establish a system to respond quickly and flexibly to the needs of patients.
We are focusing on manufacturing DX globally.
We are promoting manufacturing DX to realize our commitment to innovation for "all patients", "colleagues working together", and "the earth nurturing life" with the power of data and digital at all of our 25 or more manufacturing sites around the world. We consolidate the best practices that have achieved results at each site on the global unified platform "Global Market Place" and make it possible to introduce them at any site and exchange and deploy them between sites. This also contributes to avoiding duplicate work hours and investments in the development of new solutions.
For all patients (Patient):
1. We will further strengthen the quality assurance and stable supply of pharmaceuticals from both the perspective of predictive factory maintenance and business value creation. We will achieve predictive maintenance to prevent problems in advance. By connecting real-time anomaly detection models implemented on the cloud with the real-time data collected from the equipment, we can detect anomalies in real time and prevent sudden failures. We will also avoid deviations caused by equipment failures. This aims to achieve manufacturing without delays and prevent the occurrence of response tasks that involve a huge amount of time and work hours, such as investigating the causes, identifying the scope of the impact, devising corrective measures, and implementing necessary changes when deviations occur. We aim to improve the yield of business value (Yield Improvement) by utilizing big data obtained from sensors installed in various parts of the manufacturing equipment to develop predictive models and identify improvement opportunities in the manufacturing process.2. Inventory optimization program
We are implementing the Multi-Echelon Inventory Optimization (MEIO) program that allows real-time analysis of massive data related to manufacturing to optimize inventory levels across our supply network that spans sites and countries. MEIO enables us to quickly adapt to market changes and unexpected turmoil by considering demand patterns, manufacturing lead times, supply variations, costs, and service levels, and build a more rapid and flexible supply system for patients who need our pharmaceuticals. In the future, the introduction of machine learning is expected to further automate the supply chain, enabling autonomous operation.For colleagues working together (People)
- We are improving productivity and working style through the collaboration of digital and human. In the pharmaceutical manufacturing field, where strict compliance with Good Manufacturing Practices (GMP) is required, it is not easy to conduct training for operators due to the high level of sterile environment and the use of new manufacturing lines for initial manufacturing (Process Performance Qualification: PPQ). By using VR (Virtual Reality) and AR (Augmented Reality) for training, operators can immerse themselves in the actual working environment virtually and learn, or display devices and instructions in the real space to conduct training. Compared to the past, this enables operators to perform practical, efficient, and speedy training with fewer people and less work hours.
For the earth nurturing life (Planet)
- By utilizing big data collected from manufacturing equipment, we visualize the impact and burden on the environment and reduce environmental impact through optimization of operations and equipment.
Greg Timmons, our Global Manufacturing & Supply Japan Head, stated, "In a rapidly changing world, in order to sustainably address healthcare challenges, we must constantly pursue innovation. We are accelerating our investment in data science and digital technology, strengthening automation, AI development and standardization, data integration and democratization, talent development, predictive capabilities, and innovative collaboration and governance. AI and automation are designed to support employees in focusing on tasks that create more value. Therefore, we are putting emphasis on the digital education of employees and raising awareness of data utilization, working on DX in every aspect of the manufacturing process and operations, and striving to supply pharmaceuticals that patients need more quickly and stably."
You can find more details about our initiatives here.
※1 As of June 2024
※2 Deviation from manufacturing and testing procedures, quality systems, application content, regulatory agency requirements, standards, trends, or other compliance requirements
※3 It indicates the amount of active pharmaceutical ingredients obtained in the raw material manufacturing process. It is considered one of the parameters that indicate the normality of the process.
※4 Data democratization refers to the process and strategy of expanding access to and utilization of data to a wider range, allowing all stakeholders within the organization to make decisions using data.
Here is the English version of the press release
Please use your Futubull account to access the feature.
About Takeda Pharmaceutical
Takeda Pharmaceutical Industries, Ltd. (TSE: 4502/NYSE: TAK) aims to contribute to the health and a brighter future of people around the world. We are working to create innovative pharmaceutical products in major disease areas and business fields such as digestive system and inflammatory diseases, rare diseases, plasma fractionation products, neuroscience (neuropsychiatric disorders), oncology (cancer), and vaccines. Together with our partners, we are working to deliver new treatment options by building a strong and diverse pipeline, and to improve the quality of life of patients. Takeda Pharmaceutical is a research and development-based leading company of bio-pharmaceuticals with its headquarters in Japan, which is rooted in the value (values) of patient-centeredness based on its corporate philosophy. Based on the values that have been formed for over 2 centuries, we are working in about 80 countries and regions to fulfill our purpose in society. Please see the website for more details.
Please refer to the website for details.
This news release and the accompanying materials contain forward-looking statements, beliefs or judgments regarding Takeda's future business, future position and performance, and future outlook information based on Takeda's estimates, forecasts, targets and plans, or views. Forward-looking statements often contain terms, expressions, or negative expressions such as "targeted," "planned," "believed," "hoped," "continued," "expected," "aimed," "intended," "ensured," "will," "may," "should," "would," "could," "anticipated," "estimated," "projected," "forecast," "outlook," but are not limited to them. These forward-looking statements are based on many important assumptions about key factors and actual results may differ significantly from the future results explicitly or implicitly expected in the forward-looking information. These important factors include the general economic conditions of Takeda's global operations including Japan and the USA, the emergence and development of competitive products, changes in related laws and regulations, difficulties inherent in new product development including clinical success and the uncertainty of regulatory decisions and timing, uncertainties in the commercial success of new and existing products, difficulties or delays in the manufacturing process, fluctuations in interest rates and foreign exchange rates, claims or concerns about the safety or efficacy of products sold or candidate products in the market, health crises such as the COVID-19 pandemic, success of Takeda's environmental sustainability efforts to achieve reduction of greenhouse gas emissions or other environmental goals, and Takeda's initiatives toward business efficiency, productivity improvement or cost reduction including the integration of digital technologies including artificial intelligence (AI), and other business restructuring efforts identified in Takeda's latest annual report submitted to the US Securities and Exchange Commission on Form 20-F, which can be viewed on the Takeda website (www.takeda.com) or www.sec.gov, and other reports of Takeda. Takeda is not obligated to update any forward-looking statements contained in this news release or any forward-looking information provided by Takeda unless required by law or the rules of the securities exchange. Past performance is not indicative of future results, and information on Takeda's business results and information in this news release do not represent future business results of Takeda, nor are they predictions, expectations, warranties or estimates.
Takeda Pharmaceuticals Sp ADR
Global Manufacturing & Supply
Kumi Iiyama
080-5789-7742
[email protected]
